BARINTHUS BIOTHERAPEUTICS PL (BRNS) Fundamental Analysis & Valuation

NASDAQ:BRNS • US91864C1071

Current stock price

0.63 USD
0 (0%)
Last:

This BRNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BRNS Profitability Analysis

1.1 Basic Checks

  • BRNS had negative earnings in the past year.
  • In the past year BRNS has reported a negative cash flow from operations.
  • BRNS had negative earnings in 4 of the past 5 years.
  • BRNS had a negative operating cash flow in each of the past 5 years.
BRNS Yearly Net Income VS EBIT VS OCF VS FCFBRNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M

1.2 Ratios

  • With a Return On Assets value of -67.67%, BRNS is not doing good in the industry: 62.62% of the companies in the same industry are doing better.
  • BRNS has a Return On Equity (-89.52%) which is in line with its industry peers.
Industry RankSector Rank
ROA -67.67%
ROE -89.52%
ROIC N/A
ROA(3y)-46.65%
ROA(5y)-31.22%
ROE(3y)-58.58%
ROE(5y)-38.75%
ROIC(3y)N/A
ROIC(5y)N/A
BRNS Yearly ROA, ROE, ROICBRNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 200 400

1.3 Margins

  • BRNS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BRNS Yearly Profit, Operating, Gross MarginsBRNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. BRNS Health Analysis

2.1 Basic Checks

  • BRNS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BRNS has more shares outstanding
  • The number of shares outstanding for BRNS has been increased compared to 5 years ago.
  • BRNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BRNS Yearly Shares OutstandingBRNS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
BRNS Yearly Total Debt VS Total AssetsBRNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • BRNS has an Altman-Z score of -5.08. This is a bad value and indicates that BRNS is not financially healthy and even has some risk of bankruptcy.
  • BRNS has a worse Altman-Z score (-5.08) than 63.78% of its industry peers.
  • There is no outstanding debt for BRNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.08
ROIC/WACCN/A
WACC9.33%
BRNS Yearly LT Debt VS Equity VS FCFBRNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 7.77 indicates that BRNS has no problem at all paying its short term obligations.
  • BRNS has a Current ratio of 7.77. This is in the better half of the industry: BRNS outperforms 72.06% of its industry peers.
  • A Quick Ratio of 7.77 indicates that BRNS has no problem at all paying its short term obligations.
  • The Quick ratio of BRNS (7.77) is better than 72.45% of its industry peers.
Industry RankSector Rank
Current Ratio 7.77
Quick Ratio 7.77
BRNS Yearly Current Assets VS Current LiabilitesBRNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. BRNS Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 1.94% over the past year.
  • The Revenue for BRNS has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)1.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.06%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • BRNS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.01% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.71%
EPS Next 2Y1.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BRNS Yearly Revenue VS EstimatesBRNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BRNS Yearly EPS VS EstimatesBRNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. BRNS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BRNS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BRNS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BRNS Price Earnings VS Forward Price EarningsBRNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BRNS Per share dataBRNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.01%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BRNS Dividend Analysis

5.1 Amount

  • No dividends for BRNS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BRNS Fundamentals: All Metrics, Ratios and Statistics

BARINTHUS BIOTHERAPEUTICS PL

NASDAQ:BRNS (3/20/2026, 8:00:01 PM)

0.63

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13
Earnings (Next)05-05
Inst Owners40.9%
Inst Owner ChangeN/A
Ins Owners13.37%
Ins Owner Change0%
Market Cap25.72M
Revenue(TTM)N/A
Net Income(TTM)-66.43M
Analysts82.5
Price Target5.61 (790.48%)
Short Float %0.02%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.77%
Min EPS beat(2)33.82%
Max EPS beat(2)47.71%
EPS beat(4)2
Avg EPS beat(4)-4.09%
Min EPS beat(4)-54.49%
Max EPS beat(4)47.71%
EPS beat(8)4
Avg EPS beat(8)5.27%
EPS beat(12)7
Avg EPS beat(12)6.73%
EPS beat(16)10
Avg EPS beat(16)35.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.35
P/tB 0.43
EV/EBITDA N/A
EPS(TTM)-1.52
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS1.82
TBVpS1.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -67.67%
ROE -89.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.65%
ROA(5y)-31.22%
ROE(3y)-58.58%
ROE(5y)-38.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.63%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.77
Quick Ratio 7.77
Altman-Z -5.08
F-Score2
WACC9.33%
ROIC/WACCN/A
Cap/Depr(3y)38.57%
Cap/Depr(5y)89.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.06%
EPS Next Y4.71%
EPS Next 2Y1.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.95%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.79%
OCF growth 3YN/A
OCF growth 5YN/A

BARINTHUS BIOTHERAPEUTICS PL / BRNS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BARINTHUS BIOTHERAPEUTICS PL (BRNS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BRNS.


What is the valuation status for BRNS stock?

ChartMill assigns a valuation rating of 0 / 10 to BARINTHUS BIOTHERAPEUTICS PL (BRNS). This can be considered as Overvalued.


How profitable is BARINTHUS BIOTHERAPEUTICS PL (BRNS) stock?

BARINTHUS BIOTHERAPEUTICS PL (BRNS) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for BRNS stock?

The Earnings per Share (EPS) of BARINTHUS BIOTHERAPEUTICS PL (BRNS) is expected to grow by 4.71% in the next year.